Beam Therapeutics annual revenue
2019
2020
2021
2022
2023
2024
2025
Beam Therapeutics Revenue Growth & History (BEAM)
Beam Therapeutics reported $139.7M in revenue for fiscal 2025, an increase of 120.01% from the previous fiscal year.
View full Beam Therapeutics company overviewBeam Therapeutics annual revenue and growth
| Fiscal year | Period ended | Revenue | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $139.7M | $76.2M | +120.01% |
| 2024 | 2024-12-31 | $63.5M | −$314.2M | −83.18% |
| 2023 | 2023-12-31 | $377.7M | $316.8M | +520.01% |
| 2022 | 2022-12-31 | $60.9M | $9.1M | +17.51% |
| 2021 | 2021-12-31 | $51.8M | $51.8M | +215916.67% |
| 2020 | 2020-12-31 | $24,000 | $6,000 | +33.33% |
| 2019 | 2019-12-31 | $18,000 | — | — |
Beam Therapeutics quarterly revenue
Q2.19
Q3.19
Q1.20
Q2.20
Q3.20
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Revenue | Change | YoY growth |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $490,000 | −$8.0M | −94.21% |
| Q1 2026 | 2026-03-31 | $31.7M | $24.3M | +324.87% |
| Q4 2025 | 2025-12-31 | $114.1M | $84.0M | +279.52% |
| Q3 2025 | 2025-09-30 | $9.7M | −$4.6M | −32.03% |
| Q2 2025 | 2025-06-30 | $8.5M | −$3.3M | −28.08% |
| Q1 2025 | 2025-03-31 | $7.5M | $60,000 | +0.81% |
| Q4 2024 | 2024-12-31 | $30.1M | −$286.1M | −90.49% |
| Q3 2024 | 2024-09-30 | $14.3M | −$2.9M | −17.01% |
| Q2 2024 | 2024-06-30 | $11.8M | −$8.3M | −41.48% |
| Q1 2024 | 2024-03-31 | $7.4M | −$16.8M | −69.39% |
| Q4 2023 | 2023-12-31 | $316.2M | $296.2M | +1478.04% |
| Q3 2023 | 2023-09-30 | $17.2M | $1.4M | +8.82% |
| Q2 2023 | 2023-06-30 | $20.1M | $3.5M | +20.80% |
| Q1 2023 | 2023-03-31 | $24.2M | $15.8M | +187.10% |
| Q4 2022 | 2022-12-31 | $20.0M | −$31.0M | −60.76% |
| Q3 2022 | 2022-09-30 | $15.8M | $15.0M | +1970.64% |
| Q2 2022 | 2022-06-30 | $16.7M | $16.6M | +277433.33% |
| Q1 2022 | 2022-03-31 | $8.4M | $8.4M | +140433.33% |
| Q4 2021 | 2021-12-31 | $51.1M | $51.1M | +851050.00% |
| Q3 2021 | 2021-09-30 | $763,000 | $757,000 | +12616.67% |
| Q2 2021 | 2021-06-30 | $6,000 | $0 | 0.00% |
| Q1 2021 | 2021-03-31 | $6,000 | $0 | 0.00% |
| Q4 2020 | 2020-12-31 | $6,000 | — | — |
| Q3 2020 | 2020-09-30 | $6,000 | $0 | 0.00% |
| Q2 2020 | 2020-06-30 | $6,000 | $0 | 0.00% |
| Q1 2020 | 2020-03-31 | $6,000 | — | — |
| Q3 2019 | 2019-09-30 | $6,000 | — | — |
| Q2 2019 | 2019-06-30 | $6,000 | — | — |
Beam Therapeutics revenue growth trends
Over the last five reported fiscal years, revenue grew from $24,000 to $139.7M, a compound annual growth rate of 466.27%. Beam Therapeutics's latest reported quarter, Q2 2026, generated $490,000 in revenue, a decrease of 94.21% year over year.
About the data
What revenue means
Revenue is the top-line amount a company reports from selling goods and services before expenses are deducted. Fiscal periods can differ from calendar years, so each table includes the exact period end date.
Financial data
Standardized company financials
TickerStat standardizes company financial facts for consistent comparison. Derived growth rates use the displayed values and are not guidance or forecasts.
Review Beam Therapeutics source filings ↗Community posts
Beam reports durable protein correction with experimental AATD therapy
Beam Therapeutics ($BEAM) presented updated Phase 1/2 results for BEAM-302, its experimental gene-editing treatment for alpha-1 antitrypsin deficiency. The presentation covered 29 patients given a single dose, with follow-up extending to 18 ...
